IS2759B - CGRP-viðtakamótlyf, lyfjaefnablanda og notkun á efnablöndunum til framleiðslu á lyfi - Google Patents

CGRP-viðtakamótlyf, lyfjaefnablanda og notkun á efnablöndunum til framleiðslu á lyfi

Info

Publication number
IS2759B
IS2759B IS8055A IS8055A IS2759B IS 2759 B IS2759 B IS 2759B IS 8055 A IS8055 A IS 8055A IS 8055 A IS8055 A IS 8055A IS 2759 B IS2759 B IS 2759B
Authority
IS
Iceland
Prior art keywords
preparations
drug
manufacture
receptor antagonists
cgrp receptor
Prior art date
Application number
IS8055A
Other languages
English (en)
Other versions
IS8055A (is
Inventor
Christopher S Burgey
Theresa M Williams
Zhengwu J Deng
Diem N Nguyen
Daniel V Paone
Anthony W Shaw
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IS8055A publication Critical patent/IS8055A/is
Publication of IS2759B publication Critical patent/IS2759B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS8055A 2003-04-15 2005-09-29 CGRP-viðtakamótlyf, lyfjaefnablanda og notkun á efnablöndunum til framleiðslu á lyfi IS2759B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46308903P 2003-04-15 2003-04-15
US51035203P 2003-10-10 2003-10-10
PCT/US2004/011280 WO2004092168A1 (en) 2003-04-15 2004-04-09 Cgrp receptor antagonists

Publications (2)

Publication Number Publication Date
IS8055A IS8055A (is) 2005-09-29
IS2759B true IS2759B (is) 2011-10-15

Family

ID=33303112

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8055A IS2759B (is) 2003-04-15 2005-09-29 CGRP-viðtakamótlyf, lyfjaefnablanda og notkun á efnablöndunum til framleiðslu á lyfi

Country Status (32)

Country Link
US (6) US6953790B2 (is)
EP (2) EP1638969B1 (is)
JP (1) JP3967766B2 (is)
KR (1) KR100769030B1 (is)
CN (1) CN100384843C (is)
AR (1) AR045887A1 (is)
AT (1) ATE413400T1 (is)
AU (1) AU2004230926B2 (is)
BR (1) BRPI0409601A (is)
CA (1) CA2522220C (is)
CL (1) CL2004000788A1 (is)
CO (1) CO5640130A2 (is)
CY (1) CY1108714T1 (is)
DE (1) DE602004017608D1 (is)
DK (1) DK1638969T3 (is)
EC (1) ECSP056097A (is)
ES (1) ES2314417T3 (is)
HR (1) HRP20080666T3 (is)
IS (1) IS2759B (is)
JO (1) JO2355B1 (is)
MA (1) MA27728A1 (is)
MX (1) MXPA05011166A (is)
NO (1) NO327655B1 (is)
NZ (1) NZ543357A (is)
PE (1) PE20050020A1 (is)
PL (1) PL1638969T3 (is)
PT (1) PT1638969E (is)
RU (1) RU2308458C2 (is)
SI (1) SI1638969T1 (is)
TW (1) TWI314931B (is)
UA (1) UA82877C2 (is)
WO (2) WO2004092168A1 (is)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050008790A (ko) * 2002-06-05 2005-01-21 브리스톨-마이어스 스큅 컴퍼니 칼시토닌 유전자 관련 펩티드 수용체 길항제
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
AU2004229518B2 (en) * 2003-04-15 2010-02-18 Merck Sharp & Dohme Corp. CGRP receptor antagonists
GB0310881D0 (en) * 2003-05-12 2003-06-18 Merck Sharp & Dohme Pharmaceutical formulation
ATE461196T1 (de) * 2003-06-26 2010-04-15 Merck Sharp & Dohme Benzodiazepin-cgrp-rezeptor-antagonisten
CN1812982B (zh) * 2003-06-26 2010-10-27 默沙东公司 苯并二氮杂*cgrp受体拮抗剂
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
CA2554351A1 (en) * 2004-01-29 2005-08-11 Merck & Co., Inc. Cgrp receptor antagonists
EP1732885A1 (en) * 2004-02-23 2006-12-20 Trustees Of Tufts College Lactams as conformationally constrained peptidomimetic inhibitors
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
JP2008515895A (ja) * 2004-10-07 2008-05-15 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
CA2583534A1 (en) * 2004-10-14 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
ATE503755T1 (de) * 2004-10-22 2011-04-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
GB2423085C (en) * 2005-02-11 2011-11-09 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
GB2467060B (en) * 2005-02-11 2010-09-01 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
CA2599925A1 (en) 2005-03-14 2006-09-21 Merck & Co., Inc. Cgrp receptor antagonists
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
WO2007054809A2 (en) 2005-11-14 2007-05-18 Rinat Neuroscience Corp. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN100371327C (zh) * 2005-11-17 2008-02-27 江苏工业学院 2-氨基-6-烷氧基-3-硝基吡啶的一步合成法
CA2629409A1 (en) * 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam aryl cgrp receptor antagonists
CN101421267B (zh) * 2006-04-10 2011-10-19 默沙东公司 制备吡啶杂环cgrp拮抗剂中间体的方法
US20100286122A1 (en) * 2006-04-10 2010-11-11 Kevin Belyk CGRP Antagonist Salt
DE602007002182D1 (de) * 2006-04-10 2009-10-08 Merck & Co Inc Verfahren zur herstellung von cgrp-antagonisten
ES2328186T3 (es) * 2006-04-10 2009-11-10 MERCK & CO., INC. Procedimiento de preparacion de un intermedio de antagonista del cgrp de caprolactama.
WO2007130927A2 (en) * 2006-05-02 2007-11-15 Bristol-Myers Squibb Company Condensed tricyclic compounds as cgrp-receptor antagonists
US7470680B2 (en) 2006-05-03 2008-12-30 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
MX2008014353A (es) * 2006-05-09 2008-11-24 Merck & Co Inc Antagonistas de los receptores del peptido relacionado con el gen de calcitonina (cgrp) monociclicos sustituidos.
US7834000B2 (en) 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
AU2007258294A1 (en) * 2006-06-13 2007-12-21 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
PT2583970E (pt) * 2006-08-02 2016-02-08 Cytokinetics Inc Certas entidades químicas, composições e métodos compreendendo imidazopirimidinas
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CA2662748A1 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
AU2008257411B2 (en) 2007-05-23 2012-04-26 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
GB0712392D0 (en) * 2007-06-26 2007-08-01 Glaxo Group Ltd Novel compounds
US20090075977A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk0974
WO2009100090A1 (en) 2008-02-05 2009-08-13 Merck & Co., Inc. Prodrugs of cgrp receptor antagonist
US8796260B2 (en) 2008-02-19 2014-08-05 Merck Sharp & Dohme Corp. Imidazobenzazepine CGRP receptor antagonists
NZ587292A (en) 2008-03-04 2012-09-28 Pfizer Ltd Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
TW201004954A (en) * 2008-06-30 2010-02-01 Merck & Co Inc Solid dosage formulations of telcagepant potassium
US8623863B2 (en) 2008-10-21 2014-01-07 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
RU2535074C2 (ru) 2009-08-28 2014-12-10 Лэйбрис Байолоджикс, Инк. Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
TWI522355B (zh) 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
CA2830348A1 (en) * 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
SMT201900293T1 (it) 2011-05-20 2019-07-11 Alderbio Holdings Llc Composizioni comprendenti anticorpi anti-cgrp e loro utilizzo
EP3508501B1 (en) 2011-05-20 2024-11-06 H. Lundbeck A/S Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
DK2709662T3 (da) 2011-05-20 2019-11-04 Alderbio Holdings Llc Anvendelse af anti-cgrp- eller anti-cgrp-r-antistoffer eller antistoffragmenter til behandling eller forebyggelse af kroniske og akutte former for diarré
EA201791043A1 (ru) 2011-07-13 2017-09-29 Сайтокинетикс, Инк. Комбинированная терапия бокового амиотрофического склероза
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
KR102076118B1 (ko) 2012-02-27 2020-02-11 브리스톨-마이어스 스큅 컴퍼니 N-(5S,6S,9R)-5-아미노-6-(2,3-디플루오로페닐)-6,7,8,9-테트라히드로-5H-시클로헵타[b]피리딘-9-일-4-(2-옥소-2,3-디히드로-1H-이미다조[4,5-b]피리딘-1-일)피페리딘-1-카르복실레이트, 헤미술페이트 염
US9375002B2 (en) 2012-03-29 2016-06-28 Bayer Intellectual Property Gmbh 5-aminopyrimidine derivatives and use thereof for combating undesired plant growth
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
HK1232218A1 (zh) 2014-02-05 2018-01-05 Merck Sharp & Dohme Llc Cgrp-活性化合物的片剂制剂
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN111973740A (zh) 2014-03-21 2020-11-24 泰华制药国际有限公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
GB201417707D0 (en) 2014-10-07 2014-11-19 Viral Ltd Pharmaceutical compounds
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
CA3036632A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
US11685729B2 (en) 2018-01-19 2023-06-27 Idorsia Pharmaceuticals Ltd. C5a receptor modulators
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN108892635A (zh) * 2018-09-07 2018-11-27 江苏工程职业技术学院 一种西沙必利关键中间体的制备方法
EP3908606A4 (en) 2019-01-08 2022-11-23 H. Lundbeck A/S ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE WITH ANTI-CGRP ANTIBODIES
GB201908420D0 (en) 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
GB201908430D0 (en) * 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
BR102020007149A8 (pt) 2020-04-06 2023-09-26 H Lundbeck As Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
CA3190176A1 (en) 2020-07-29 2022-02-03 Allergan Pharmaceuticals International Limited Treatment of migraine
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
KR20230157986A (ko) 2021-03-02 2023-11-17 체게에르페 다이어그노스틱스 게엠베하 편투통 발생의 치료 및/또는 저감
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
MX2024003952A (es) 2021-09-27 2024-05-27 Allergan Pharmaceuticals Int Ltd Combinación que comprende atogepant para tratar la migraña.
CN116903616B (zh) * 2023-07-17 2025-08-01 江西同和药业股份有限公司 一种瑞美吉泮中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
JP2002525371A (ja) * 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
DE69909811T2 (de) 1998-09-30 2004-01-29 Taisho Pharmaceutical Co Ltd Substituierte isoxazolylthiophenverbindungen
KR20050008790A (ko) * 2002-06-05 2005-01-21 브리스톨-마이어스 스큅 컴퍼니 칼시토닌 유전자 관련 펩티드 수용체 길항제
AU2004229518B2 (en) * 2003-04-15 2010-02-18 Merck Sharp & Dohme Corp. CGRP receptor antagonists

Also Published As

Publication number Publication date
KR20050121734A (ko) 2005-12-27
US7893052B2 (en) 2011-02-22
CO5640130A2 (es) 2006-05-31
US20080280857A1 (en) 2008-11-13
KR100769030B1 (ko) 2007-10-22
PE20050020A1 (es) 2005-02-18
US7235545B2 (en) 2007-06-26
RU2005135440A (ru) 2006-03-20
HRP20080666T3 (en) 2009-01-31
AR045887A1 (es) 2005-11-16
US20070225272A1 (en) 2007-09-27
EP1638969A2 (en) 2006-03-29
CN1802376A (zh) 2006-07-12
CA2522220A1 (en) 2004-10-28
RU2308458C2 (ru) 2007-10-20
US20090192139A1 (en) 2009-07-30
HK1090922A1 (en) 2007-01-05
SI1638969T1 (sl) 2009-02-28
US20100298303A1 (en) 2010-11-25
EP1638969B1 (en) 2008-11-05
PT1638969E (pt) 2009-01-16
JP3967766B2 (ja) 2007-08-29
UA82877C2 (en) 2008-05-26
IS8055A (is) 2005-09-29
DE602004017608D1 (de) 2008-12-18
BRPI0409601A (pt) 2006-04-18
ATE413400T1 (de) 2008-11-15
JP2006523697A (ja) 2006-10-19
US20040229861A1 (en) 2004-11-18
EP2039694B1 (en) 2014-03-26
WO2004092166A3 (en) 2005-01-20
US7772224B2 (en) 2010-08-10
AU2004230926A1 (en) 2004-10-28
US20050256098A1 (en) 2005-11-17
AU2004230926B2 (en) 2008-07-17
EP2039694A1 (en) 2009-03-25
NO20055375L (no) 2005-11-14
US7452903B2 (en) 2008-11-18
ECSP056097A (es) 2006-03-01
NO327655B1 (no) 2009-09-07
WO2004092166A2 (en) 2004-10-28
WO2004092168A1 (en) 2004-10-28
CY1108714T1 (el) 2014-04-09
JO2355B1 (en) 2006-12-12
MXPA05011166A (es) 2005-12-14
MA27728A1 (fr) 2006-01-02
NZ543357A (en) 2008-08-29
US6953790B2 (en) 2005-10-11
PL1638969T3 (pl) 2009-04-30
TW200505903A (en) 2005-02-16
DK1638969T3 (da) 2009-01-26
ES2314417T3 (es) 2009-03-16
CL2004000788A1 (es) 2005-02-25
US7534784B2 (en) 2009-05-19
CA2522220C (en) 2009-06-23
CN100384843C (zh) 2008-04-30
TWI314931B (en) 2009-09-21

Similar Documents

Publication Publication Date Title
IS2759B (is) CGRP-viðtakamótlyf, lyfjaefnablanda og notkun á efnablöndunum til framleiðslu á lyfi
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
NO20052285D0 (no) Faste, partikkelformige, antifungale preparater for farmasoytisk anvendelse
DK1732917T3 (da) Udvalgte CGRP-antagonister, fremgangsmåde til fremstilling deraf, samt anvendelse deraf som lægemiddel
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
DK1951661T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser deraf
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
DK1523488T3 (da) Nye thiophenglycosidderivater, fremgangsmåder til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
KR20050009999A (ko) 약제학적 제제
DK1448591T3 (da) 17-alpha-alkyl-17-beta-oxy-estratriener og mellemprodukter til fremstilling heraf, anvendelse af 17-alpha-alkyl-17-beta-oxy-estratriener til fremstilling af lægemidler samt farmaceutiske præparater
DK1427730T3 (da) Nye dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
DE60105922D1 (de) Tragbares, autarkes Medikamenteninfusionsgerät
NO20053224D0 (no) Patient controlled drug administration device.
DK1951658T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser
DE602004028934D1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
DK1463759T3 (da) Ligand for den G-proteinkoblede receptor GPR43 og anvendelser deraf
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1513836T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1831240T3 (da) 18-methyl-19-nor-17pregn-4-en-21, 17-carbolactoner samt farmaceutiske præparater, der indeholder disse
NO20051983D0 (no) 3-fenyl-substituert pyridoindolon, fremstilling derav og terapeutisk anvendelse derav.
NO20040499L (no) Substituerte pyridin-4-oner og deres andvendelse som gonadotropin-frigjorende hormon reseptor antagonister.
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
DK1753725T3 (da) Tetra-hydro-iso-quinolinsulfonamidderivater, fremstilling og terapeutisk anvendelse heraf.
DE50304722D1 (de) Fungizide Wirkstoffkombinationen